Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects approximately 1 in 2000 people over their lifetime (Cleveland and Rothstein, 2001) . ALS is characterized by a selective loss of upper and lower motor neurons that initiates a progressive paralysis with muscle wasting in mid-life, and is usually fatal within 1-5 years after onset. Approximately 5-10% of all ALS cases are familial, and at least five causal genes have been so far identified in individuals affected with familial ALS (SOD1, ALS2, senataxin, vesicle-trafficking protein/ synaptobrevin-associated membrane protein, and TDP-43), although the mechanism underlying motor neuron death of familial ALS pathology has not been elucidated (Rosen et al., 1993; Hadano et al., 2001; Yang et al., 2001; Chen et al., 2004; Nishimura et al., 2004; Yokoseki et al., 2008; Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008) . However, sporadic ALS accounts for the majority of all ALS cases, and one clue to the pathomechanism of sporadic ALS, low editing efficiency of GluR2 mRNA, has been elucidated (Takuma et al., 1999; Kawahara et al., 2004) .
One of the most plausible hypotheses for selective neuronal death in sporadic ALS is excitotoxicity mediated by abnormally Ca 2+ -permeable a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, a subtype of ionotropic glutamate receptor (GluR) (Kwak and Kawahara, 2005; Carriedo et al., 1996; Lu et al., 1996) . The contribution of excessive Ca 2+ influx through glutamate receptors to the death of motor neurons is the basis for the recent suggestion that deficient GluR2 Q/R site-RNA editing might play a role in ALS (Kawahara et al., 2004; Kwak and Kawahara, 2005) . A decrease or loss of RNA editing function occurring specifically in motor neurons could lead to AMPAchannels highly permeable to Ca 2+ , mimicking or exacerbating the overexcitation of glutamate receptors due to excitatory amino acid transporter loss. The Ca 2+ conductance of AMPA receptors differs markedly depending on whether the GluR2 subunit is a component of the receptor. AMPA receptors that contain at least one GluR2 subunit have low Ca 2+ conductance, whereas those lacking a GluR2 subunit are Ca 2+ permeable (Hollmann et al., 1991; Verdoorn et al., 1991; Burnashev et al., 1992) . These properties of GluR2 are generated post-transcriptionally by RNA editing at the glutamine/ arginine (Q/R) site in the putative second membrane domain, during which the glutamine codon is substituted by an arginine Marked reduction of RNA editing at the glutamine (Q)/arginine (R) site of the glutamate receptor subunit type 2 (GluR2) in motor neurons may be a contributory cause of neuronal death specifically in sporadic ALS. It has been shown that deregulation of RNA editing of several mRNAs plays a causative role in diseases of the central nervous system such as depression. We analyzed the effects of eight antidepressants on GluR2 Q/R site-RNA editing in a modified HeLa cell line that stably expresses halfedited GluR2 pre-mRNA. We also measured changes in RNA expression levels of adenosine deaminase acting on RNA type 2 (ADAR2), the specific RNA editing enzyme of the GluR2 Q/R site, and GluR2, in order to assess the molecular mechanism causing alteration of this site-editing. The editing efficiency at the GluR2 Q/R site was significantly increased after treatment with seven out of eight antidepressants at a concentration of no more than 10 mM for 24 h. The relative abundance of ADAR2 mRNA to GluR2 premRNA or to b-actin mRNA was increased after treatment with six of the effective antidepressants, whereas it was unchanged after treatment with milnacipran. Our results suggest that antidepressants have the potency to enhance GluR2 Q/R site-editing by either upregulating the ADAR2 mRNA expression level or other unidentified mechanisms. It may be worth investigating the in vivo efficacy of antidepressants with a specific therapeutic strategy for sporadic ALS in view. ß 2009 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
